Panobinostat (LBH589) Clinical Trials

Size	Price	Qty
10mg	USD 147
50mg	USD 270

Clinical Trials

Panobinostat has been evaluated across numerous clinical trials spanning Phase 1 through Phase 4, sponsored by academic institutions, cooperative groups, and pharmaceutical companies like Novartis and Celgene. Ranging in status from completed landmark Phase 3 studies to terminated, withdrawn, or unknown protocols, these trials primarily target hematologic malignancies, including multiple myeloma, acute myeloid leukemia, myelodysplastic syndromes, and Hodgkin's lymphoma. Additionally, research addresses pediatric and adult solid tumors such as diffuse intrinsic pontine glioma, melanoma, and non-small cell lung cancer.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05725200	RECRUITING	Metastatic Colorectal Cancer	Oslo University Hospital	2022-09-27	PHASE2
NCT02386800	ACTIVE_NOT_RECRUITING	Primary Myelofibrosis; Polycythemia Vera; Graft Versus Host Disease; Acute Myeloid Leukemia; Thalassemia	Novartis Pharmaceuticals	2015-03-05	PHASE4
NCT01245179	RECRUITING	Sickle Cell Disease	Abdullah Kutlar	2010-11	PHASE1
NCT03632317	WITHDRAWN	Glioma; Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	2019-10	PHASE2
NCT06240520	UNKNOWN	Hiv	Erasmus Medical Center	2024-04	PHASE1; PHASE2
NCT02506959	COMPLETED	Plasma Cell Leukemia; Plasmacytoma; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	M.D. Anderson Cancer Center	2015-09-14	PHASE2
NCT04897880	TERMINATED	Rhabdoid Tumor; Atypical Teratoid/Rhabdoid Tumor; Malignant Rhabdoid Tumor; Recurrent Brain Tumor, Childhood	Australian & New Zealand Children's Haematology/Oncology Group	2019-01-09	PHASE2
NCT04341311	TERMINATED	Diffuse Intrinsic Pontine Glioma; Pediatric Brainstem Glioma; Pediatric Brainstem Gliosarcoma, Recurrent; Pediatric Cancer; Pediatric Brain Tumor; Diffuse Glioma	Dana-Farber Cancer Institute	2020-08-10	PHASE1
NCT04315064	COMPLETED	Medulloblastoma	The University of Texas Health Science Center, Houston	2020-04-21	EARLY_PHASE1
NCT04326764	TERMINATED	Acute Myeloid Leukaemia (AML); Myelodysplastic Syndromes (MDS)	Goethe University	2018-07-24	PHASE3
NCT02471430	COMPLETED	HIV Infection	Massachusetts General Hospital	2016-05	PHASE1; PHASE2
NCT04956302	TERMINATED	Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	Abdullah Khan	2021-09-27	PHASE1
NCT04804709	TERMINATED	Diffuse Intrinsic Pontine Glioma; Diffuse Pontine and Thalamic Gliomas; Diffuse Midline Glioma, H3 K27M-Mutant	Columbia University	2021-07-28	PHASE1
NCT02890069	COMPLETED	Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma	Novartis Pharmaceuticals	2016-10-14	PHASE1
NCT02717455	COMPLETED	Glioma	Pediatric Brain Tumor Consortium	2016-06-28	PHASE1
NCT02961816	WITHDRAWN	Lymphoma	M.D. Anderson Cancer Center	2017-06	PHASE2
NCT03982134	WITHDRAWN	Melanoma; Non Small Cell Lung Cancer	Muhammad Furqan	2019-09	PHASE1
NCT03566199	COMPLETED	Diffuse Intrinsic Pontine Glioma	Sabine Mueller, MD, PhD	2018-05-22	PHASE1; PHASE2
NCT03256045	TERMINATED	Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	University of Washington	2018-02-08	PHASE2
NCT02756663	WITHDRAWN	Multiple Myeloma	Novartis Pharmaceuticals	2016-12	PHASE2
NCT03878524	TERMINATED	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma	OHSU Knight Cancer Institute	2020-04-01	PHASE1
NCT01496118	COMPLETED	Multiple Myeloma	SCRI Development Innovations, LLC	2011-12	PHASE1; PHASE2
NCT02802163	WITHDRAWN	Multiple Myeloma	H. Lee Moffitt Cancer Center and Research Institute	2017-06	PHASE1; PHASE2
NCT04341311	Terminated	Diffuse Intrinsic Pontine Glioma\|Pediatric Brainstem Glioma\|Pediatric Brainstem Gliosarcoma Recurrent\|Pediatric Cancer\|Pediatric Brain Tumor\|Diffuse Glioma	Dana-Farber Cancer Institute\|Celgene\|Secura Bio Inc.	2020-08-10	Phase 1
NCT01433445	COMPLETED	Idiopathic Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia-Vera Myelofibrosis	Novartis Pharmaceuticals	2011-11-01	PHASE1
NCT02722941	COMPLETED	Multiple Myeloma	H. Lee Moffitt Cancer Center and Research Institute	2016-06-10	PHASE2
NCT01301807	COMPLETED	Non-Secretory Plasma Cell Myeloma; Plasmacytosis; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	M.D. Anderson Cancer Center	2011-07-28	PHASE1
NCT02654990	COMPLETED	Multiple Myeloma	pharmaand GmbH	2016-04-27	PHASE2
NCT03632317	Withdrawn	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	2019-10	Phase 2
NCT03982134	Withdrawn	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	2019-09	Phase 1
NCT00946647	COMPLETED	Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Acute Myeloid Leukemia	Novartis Pharmaceuticals	2009-12-02	PHASE1; PHASE2
NCT01965353	COMPLETED	Multiple Myeloma in Relapse	Dana-Farber Cancer Institute	2013-10	PHASE1
NCT01440582	COMPLETED	Myeloma	M.D. Anderson Cancer Center	2013-02-18	PHASE1
NCT02588339	COMPLETED	Graft Versus Host Disease; GVHD	H. Lee Moffitt Cancer Center and Research Institute	2016-03-04	PHASE2
NCT01802879	COMPLETED	Hematologic Neoplasms	Novartis Pharmaceuticals	2013-06-24	PHASE2
NCT04326764	Terminated	Acute Myeloid Leukaemia (AML)\|Myelodysplastic Syndromes (MDS)	Goethe University\|Stichting Hemato-Oncologie voor Volwassenen Nederland\|Polish Adult Leukemia Group\|Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung	2018-07-24	Phase 3
NCT01693601	COMPLETED	Myelofibrosis	John Mascarenhas	2013-01	PHASE1; PHASE2
NCT02057640	COMPLETED	Multiple Myeloma; Kahler Disease; Plasma-Cell Myeloma; Myelomatosis	Jason Valent	2014-05-22	PHASE1; PHASE2
NCT02676323	TERMINATED	Acute Myeloid Leukemia; Myelodysplastic Syndrome	St. Jude Children's Research Hospital	2016-05-03	PHASE1
NCT03515915	Unknown status	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	2018-04-23	--
NCT01451268	UNKNOWN	Myelodysplastic Syndrome; Acute Myeloid Leukemia	Johann Wolfgang Goethe University Hospital	2011-01	PHASE1; PHASE2
NCT02518750	TERMINATED	Acute Lymphoblastic Leukemia; Lymphoma, Non-Hodgkin's; Leukemia, T-Cell; Leukemia, B-Cell	St. Jude Children's Research Hospital	2016-11-23	PHASE2
NCT02290431	COMPLETED	Relapse/Refractory Multiple Myeloma	Novartis Pharmaceuticals	2014-12-16	PHASE2
NCT00532675	COMPLETED	Multiple Myeloma	Novartis Pharmaceuticals	2008-04-22	PHASE1
NCT02032810	COMPLETED	Melanoma; Skin Cancer	H. Lee Moffitt Cancer Center and Research Institute	2014-01-07	PHASE1
NCT02720510	TERMINATED	Multiple Myeloma	Novartis Pharmaceuticals	2016-06-14	PHASE2
NCT01169636	COMPLETED	Hodgkin's Lymphoma	M.D. Anderson Cancer Center	2011-01-31	PHASE1; PHASE2
NCT01032148	TERMINATED	Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma	Roswell Park Cancer Institute	2009-12	PHASE1
NCT01336842	COMPLETED	Solid Tumors; Non-Small Cell Lung Cancer (NSCLC)	University of California, Davis	2011-04	PHASE1
NCT01651039	COMPLETED	Multiple Myeloma	Ajai Chari	2012-07	PHASE2
NCT01460940	COMPLETED	Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma	Ohio State University Comprehensive Cancer Center	2011-10-13	PHASE2
NCT01341834	UNKNOWN	Nasopharyngeal Carcinoma, Lymphomas, Any EBV+ Solid Tumour	National Cancer Centre, Singapore	2010-03	PHASE1
NCT01261247	COMPLETED	Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia	Mayo Clinic	2011-01-17	PHASE2
NCT00840346	COMPLETED	Acute Myeloblastic Leukaemia	PETHEMA Foundation	2009-09	PHASE1; PHASE2
NCT01549431	COMPLETED	Multiple Myeloma	Emory University	2012-01	PHASE1
NCT01238692	COMPLETED	Diffuse Large B Cell Lymphoma	Sarit Assouline	2010-11	PHASE2
NCT00918333	COMPLETED	Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; B-cell Adult Acute Lymphoblastic Leukemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Multiple Myeloma; Splenic Marginal Zone Lymphoma; T-cell Adult Acute Lymphoblastic Leukemia; Waldenström Macroglobulinemia	Mayo Clinic	2009-06	PHASE1; PHASE2
NCT01463046	COMPLETED	Acute Myeloid Leukemia; Advanced Myelodysplastic Syndrome	University of California, San Francisco	2012-01	PHASE1
NCT01582009	TERMINATED	Clear Cell Renal Cell Carcinoma; Recurrent Renal Cell Cancer; Stage III Renal Cell Cancer; Stage IV Renal Cell Cancer	Roswell Park Cancer Institute	2010-03	PHASE1; PHASE2
NCT01321346	COMPLETED	Lymphoblastic Leukemia, Acute, Childhood; Myelogenous Leukemia, Acute, Childhood; Hodgkin's Disease; Non-Hodgkin's Lymphoma	Therapeutic Advances in Childhood Leukemia Consortium	2011-03	PHASE1
NCT01111526	COMPLETED	Graft-Versus-Host Disease	H. Lee Moffitt Cancer Center and Research Institute	2010-04	PHASE1; PHASE2
NCT01023308	COMPLETED	Multiple Myeloma	Novartis Pharmaceuticals	2009-12-21	PHASE3
NCT01298934	UNKNOWN	Primary Myelofibrosis; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Post-Essential Thrombocythemia Related Myelofibrosis	Ronald Hoffman	2009-09	PHASE1; PHASE2
NCT00907179	TERMINATED	Non-Small Cell Lung Cancer	University of Pittsburgh	2009-07	PHASE1
NCT02145715	UNKNOWN	Multiple Myeloma	Prof Jamie Cavenagh	2013-01	PHASE1; PHASE2
NCT00978432	TERMINATED	Diffuse Large B-cell Lymphoma	Anne Beaven, MD	2012-02	PHASE2
NCT00985946	TERMINATED	Neuroendocrine Tumors	University of Wisconsin, Madison	2010-05	PHASE2
NCT00777049	COMPLETED	Breast Cancer	Translational Research in Oncology	2009-02	PHASE2
NCT01658241	COMPLETED	Nodal Lymphoma; Lymphoma With Cutaneous Involvement; Lymphoma in Leukemic Phase; Marrow Involvement With Lymphoma; Multiple Myeloma	Peter MacCallum Cancer Centre, Australia	2012-07-16	PHASE2
NCT00878436	COMPLETED	Prostate Cancer; Prostatic Neoplasms	NYU Langone Health	2009-06	PHASE1; PHASE2
NCT01238965	TERMINATED	Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer	University of Southern California	2010-10	PHASE1
NCT00925132	TERMINATED	Metastatic Melanoma	University of Iowa	2009-12	PHASE1; PHASE2
NCT01504776	COMPLETED	Mantle Cell Lymphoma	Anand Jillella	2011-04	PHASE1
NCT00997399	COMPLETED	Advanced Solid Tumors	Novartis Pharmaceuticals	2010-03	PHASE1
NCT01242774	COMPLETED	Acute Myeloid Leukemia (AML)	Novartis Pharmaceuticals	2010-10	PHASE1
NCT01613976	COMPLETED	Myelodysplastic Syndromes (MDS); Chronic Myelomonocytic Leukemia (CMML); Acute Myeloid Leukemia (AML)	Novartis Pharmaceuticals	2012-08	PHASE1
NCT01884428	UNKNOWN	Hodgkin's Lymphoma	Armando Santoro, MD	2011-07	PHASE1
NCT01005797	COMPLETED	Renal Cancer; Non Small Cell Lung Cancer (NSCLC); Soft Tissue Sarcoma	Medical University of South Carolina	2009-11	PHASE1
NCT00967044	COMPLETED	Lymphoma	M.D. Anderson Cancer Center	2009-11	PHASE1; PHASE2
NCT01083602	COMPLETED	Relapsed and Bortezomib Refractory Multiple Myeloma; Refractory Multiple Myeloma; Multiple Myeloma in Relapse	Novartis Pharmaceuticals	2010-06	PHASE2
NCT01194908	TERMINATED	Breast Cancer; Breast Tumors; Breast Neoplasms	Emory University	2010-07	PHASE1; PHASE2
NCT00901147	COMPLETED	Peripheral T-cell Lymphoma (Not Otherwise Specified); Angioimmunoblastic T-cell Lymphoma; Extranodal NK/T-cell Lymphoma Nasal Type; Enteropathy- Type T-cell Lymphoma; Hepatosplenic T-cell Lymphoma; Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative); Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant	Singapore General Hospital	2009-11	PHASE2
NCT01523834	COMPLETED	Diffuse Large B-cell Lymphoma	Fondazione Italiana Linfomi - ETS	2011-02	PHASE2
NCT01175109	UNKNOWN	Chordoma	Deric M Park MD	2011-10	PHASE1
NCT00532389	COMPLETED	Multiple Myeloma	Novartis Pharmaceuticals	2007-10	PHASE1
NCT01324635	TERMINATED	Recurrent Glioma; High-grade Meningioma; Brain Metastasis	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	2012-05	PHASE1
NCT00859222	COMPLETED	Malignant Glioma	Patrick Y. Wen, MD	2009-03	PHASE1; PHASE2
NCT01680094	COMPLETED	HIV Infection	University of Aarhus	2012-09	PHASE1; PHASE2
NCT00742027	COMPLETED	Classical Hodgkin's Lymphoma	Novartis Pharmaceuticals	2008-09-16	PHASE2
NCT01013597	COMPLETED	Thyroid Carcinoma	University of Wisconsin, Madison	2010-01	PHASE2
NCT01105312	COMPLETED	Breast Cancer	Alliance for Clinical Trials in Oncology	2010-09	PHASE1; PHASE2
NCT00738751	COMPLETED	Lung Cancer; Head and Neck Cancer	H. Lee Moffitt Cancer Center and Research Institute	2008-11	PHASE1
NCT01282476	TERMINATED	Diffuse Large B Cell Lymphoma	Massachusetts General Hospital	2011-06	PHASE2
NCT00891033	TERMINATED	Multiple Myeloma	University of Arkansas	2009-04	PHASE1
NCT00691938	COMPLETED	Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	Washington University School of Medicine	2008-06	PHASE1; PHASE2
NCT00939159	TERMINATED	Myelodysplastic Syndrome	M.D. Anderson Cancer Center	2009-08	PHASE2
NCT00425555	COMPLETED	Cutaneous T-Cell Lymphoma	Novartis Pharmaceuticals	2007-01	PHASE2
NCT00878904	COMPLETED	Unspecified Adult Solid Tumor, Protocol Specific	University of California, San Francisco	2009-09-13	PHASE1
NCT00686218	COMPLETED	Leukemia	City of Hope Medical Center	2008-05	PHASE1
NCT01065467	COMPLETED	Melanoma; Malignant Melanoma	Dana-Farber Cancer Institute	2010-02	PHASE1
NCT01528501	TERMINATED	Metastatic Gastric Cancer	Technical University of Munich	2009-06	PHASE2
NCT00962507	COMPLETED	Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm	City of Hope Medical Center	2009-07	PHASE1
NCT00743288	COMPLETED	Multiple Myeloma	Oncotherapeutics	2008-07	PHASE1; PHASE2
NCT01007968	COMPLETED	Advanced Solid Tumors	Novartis Pharmaceuticals	2010-03	PHASE1
NCT01034657	TERMINATED	Myelodysplastic Syndrome (MDS)	Novartis Pharmaceuticals	2009-11	PHASE2
NCT01034163	COMPLETED	Hodgkin's Lymphoma	Novartis Pharmaceuticals	2010-06	PHASE3
NCT01055483	COMPLETED	Acute Myeloid Leukemia	Novartis Pharmaceuticals	2009-09	PHASE1
NCT00880269	COMPLETED	Refractory Leukemia; Acute Myelogenous Leukemia	Novartis Pharmaceuticals	2009-08	PHASE2
NCT01136499	COMPLETED	Soft Tissue Sarcoma	Centre Leon Berard	2010-01	PHASE2
NCT00690677	COMPLETED	Colorectal Cancer	Swedish Medical Center	2008-06	PHASE2
NCT01159418	UNKNOWN	Advanced Solid Tumors	Southern Europe New Drug Organization	2008-06	PHASE1
NCT00663832	COMPLETED	Prostate Cancer	Novartis Pharmaceuticals	2008-02	PHASE1
NCT00936611	COMPLETED	Waldenstrom's Macroglobulinemia	Dana-Farber Cancer Institute	2009-07	PHASE2
NCT00931762	TERMINATED	Primary Myelofibrosis; Post-Polycythemia Vera; Post-Essential Thrombocytopenia	Novartis Pharmaceuticals	2009-08-31	PHASE2
NCT01055795	COMPLETED	Advanced Solid Tumors	Herbert Hurwitz	2010-03	PHASE1
NCT00958022	TERMINATED	Small Cell Lung Cancer	Ahmad Tarhini	2009-09	PHASE1
NCT00567879	TERMINATED	Breast Cancer	Novartis Pharmaceuticals	2008-04	PHASE1; PHASE2
NCT01115036	WITHDRAWN	Recurrent Glioblastoma	Duke University	2010-04	PHASE2
NCT01090973	TERMINATED	Non-Hodgkin's Lymphoma	H. Lee Moffitt Cancer Center and Research Institute	2010-03	PHASE2
NCT00594230	TERMINATED	Myelodysplastic Syndromes (MDS)	SCRI Development Innovations, LLC	2008-01	PHASE2
NCT00570284	COMPLETED	Cancer	Novartis Pharmaceuticals	2007-11	PHASE1
NCT01056601	TERMINATED	Pancreatic Cancer	Masonic Cancer Center, University of Minnesota	2010-09	PHASE2
NCT00823290	TERMINATED	Hepatocellular Carcinoma	University of Erlangen-Nürnberg Medical School	2009-01	PHASE1
NCT00667862	COMPLETED	Prostate Cancer	Novartis Pharmaceuticals	2008-03-18	PHASE2
NCT01160731	WITHDRAWN	Lung Cancer	Cancer Trials Ireland	2009-11	PHASE1
NCT00723203	TERMINATED	Leukemia	City of Hope Medical Center	2008-04	PHASE2
NCT00993642	WITHDRAWN	Breast Cancer	Tulane University Health Sciences Center	2009-09	EARLY_PHASE1
NCT00788931	COMPLETED	HER-2 Positive Breast Cancer; Metastatic Breast Cancer	Novartis Pharmaceuticals	2008-12	PHASE1
NCT00556088	COMPLETED	Solid Tumors	SCRI Development Innovations, LLC	2007-12	PHASE1
NCT00873002	TERMINATED	Liver Cancer	Case Comprehensive Cancer Center	2009-03	PHASE1
NCT00503451	COMPLETED	Non-Hodgkin Lymphoma; Neoplasms	Novartis Pharmaceuticals	2007-09	PHASE1
NCT00550277	COMPLETED	Renal Cell Carcinoma	SCRI Development Innovations, LLC	2008-01	PHASE2
NCT00777335	TERMINATED	Breast Cancer	Translational Research in Oncology	2009-02	PHASE2
NCT00550199	TERMINATED	Solid Tumors	SCRI Development Innovations, LLC	2007-11	PHASE1
NCT00670553	COMPLETED	Prostate Cancer; Head & Neck Cancer; Esophageal Cancer	Novartis Pharmaceuticals	2008-09	PHASE1
NCT00621244	COMPLETED	Lymphoma; Leukemia; Multiple Myeloma	Novartis Pharmaceuticals	2003-03-01	PHASE1; PHASE2
NCT00739414	COMPLETED	Cancer; Advanced Solid Tumor	Novartis Pharmaceuticals	2008-07	PHASE1
NCT00490776	TERMINATED	Cutaneous T-Cell Lymphoma	Novartis Pharmaceuticals	2007-07-05	PHASE2
NCT01222936	COMPLETED	Small Cell Lung Carcinoma	Southern Europe New Drug Organization	2008-05	PHASE2
NCT00848523	TERMINATED	Recurrent Malignant Gliomas	Neurological Surgery, P.C.	2008-11	PHASE2
NCT00632489	COMPLETED	Breast Cancer	SCRI Development Innovations, LLC	2008-05	PHASE1
NCT00535951	COMPLETED	Carcinoma, Non-Small-Cell Lung; Mesothelioma	Novartis Pharmaceuticals	2007-11	PHASE1
NCT00699296	TERMINATED	Cutaneous T-Cell Lymphoma; Leukemia-Lymphoma, Adult T-Cell	Novartis Pharmaceuticals	2008-05	PHASE2
NCT00493766	TERMINATED	Hormone Refractory Prostate Cancer	Novartis Pharmaceuticals	2006-05	PHASE1
NCT00472368	COMPLETED	Cancer Patients With Advanced Solid Tumors Including Lymphoma or Chronic Hematological Malignancies	Novartis Pharmaceuticals	2007-05	PHASE1
NCT00445068	TERMINATED	Multiple Myeloma	Novartis Pharmaceuticals	2007-04-16	PHASE2
NCT00412997	COMPLETED	Tumors; Cutaneous T-Cell Lymphoma	Novartis	2006-11	PHASE1
NCT00451035	TERMINATED	Chronic Myeloid Leukemia in Chronic Phase	Novartis Pharmaceuticals	2007-02-19	PHASE2
NCT00449761	TERMINATED	Leukemia, Myeloid, Chronic	Novartis Pharmaceuticals	2007-02-23	PHASE2
NCT00419536	TERMINATED	Hormone Refractory Prostate Cancer Disease	Novartis Pharmaceuticals	2006-05	PHASE1
NCT01028313	WITHDRAWN	Chronic Graft-Versus-Host Disease	SCRI Development Innovations, LLC		PHASE2

(data from https://clinicaltrials.gov, updated on 2023-02-21)

Check the Panobinostat (LBH589) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Panobinostat is a potent broad-spectrum histone deacetylase inhibitor that binds to the enzymatic active sites of histone deacetylases, blocking the deacetylation of histone and non-histone proteins to disrupt downstream gene transcription and protein stability, which subsequently triggers cellular autophagy and apoptosis. This functional blockade suppresses tumor cell proliferation, providing the mechanistic rationale for its clinical investigation in hematologic and solid malignancies such as multiple myeloma, acute myeloid leukemia, and diffuse intrinsic pontine glioma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).